Isocarboxazid
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
fospropofol
Propofol derivative · Sedative-hypnotic
Propofol derivativeSedative-hypnotic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
7 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 7 →
- IsocarboxazidSevereDatabaseDDInter
- OliceridineSevereDatabaseDDInter
- PhenelzineSevereDatabaseDDInter
- RemimazolamSevereDatabaseDDInter
Mechanism
Prodrug of propofol, which acts as a GABAA receptor agonist.
Indications
sedation in otherwise-healthy individuals
Dosing
- Adult
- 2 to 8 mg/kg IV (delivered as bolus or short infusion over 5–10 min); optimum dose for sedation is about 6.5 mg/kg
Pharmacokinetics
Onset
loss of consciousness in about 10 min; prolonged onset (time to peak effect, 8–13 min)
Duration
sedative effect approximately 45 min; slow recovery
Metabolism
hydrolyzed by alkaline phosphatase to yield propofol, phosphate, and formaldehyde
Contraindications
- discontinued for clinical use in the U.S. due to prolonged onset, slow recovery, and significant perianal pruritus
Side effects
Common
less pain on injection compared to propofolsignificant perianal pruritus
Drug interactions
Oliceridine
Severe
Database
Clinical effect not specified
Source: DDInter
Phenelzine
Severe
Database
Clinical effect not specified
Source: DDInter
Remimazolam
Severe
Database
Clinical effect not specified
Source: DDInter
Selegiline
Severe
Database
Clinical effect not specified
Source: DDInter
Sodium Oxybate
Severe
Database
Clinical effect not specified
Source: DDInter
Tranylcypromine
Severe
Database
Clinical effect not specified
Source: DDInter
5 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Ask House about fospropofol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team